Literature DB >> 30199251

Phosphonamidate Prodrugs of a Butyrophilin Ligand Display Plasma Stability and Potent Vγ9 Vδ2 T Cell Stimulation.

Nicholas A Lentini1, Benjamin J Foust1, Chia-Hung Christine Hsiao2, Andrew J Wiemer2,3, David F Wiemer1,4.   

Abstract

Small organophosphorus compounds stimulate Vγ9 Vδ2 T cells if they serve as ligands of butyrophilin 3A1. Because the most potent natural ligand is ( E)-4-hydroxy-3-methyl-but-2-enyl diphosphate (HMBPP), which is the last intermediate in bacterial biosynthesis of isoprenoids that is not found in mammalian metabolism, activation of these T cells represents an important component of the immune response to bacterial infections. To identify butyrophilin ligands that may have greater plasma stability, and clinical potential, we have prepared a set of aryl phosphonamidate derivatives (9a-i) of the natural ligand. Testing of these new compounds in assays of T cell response has revealed that this strategy can provide compounds with high potency for expansion of Vγ9 Vδ2 T cells (9f, EC50 = 340 pM) and interferon γ production in response to loaded K562 cells (9e, EC50 = 62 nM). Importantly, all compounds of this class display extended plasma stability ( t1/2 > 24 h). These findings increase our understanding of metabolism of butyrophilin ligands and the structure-activity relationships of phosphonamidate prodrugs.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30199251      PMCID: PMC6703555          DOI: 10.1021/acs.jmedchem.8b00655

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  37 in total

Review 1.  T cell anergy.

Authors:  Ronald H Schwartz
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

2.  Mixed Aryl Phosphonate Prodrugs of a Butyrophilin Ligand.

Authors:  Benjamin J Foust; Michael M Poe; Nicholas A Lentini; Chia-Hung Christine Hsiao; Andrew J Wiemer; David F Wiemer
Journal:  ACS Med Chem Lett       Date:  2017-08-09       Impact factor: 4.345

3.  Effect of short-term treatment with pivalic acid containing antibiotics on serum carnitine concentration--a risk irrespective of age.

Authors:  K Abrahamsson; E Holme; U Jodal; S Lindstedt; I Nordin
Journal:  Biochem Mol Med       Date:  1995-06

4.  Metabolism of GS-7340, a novel phenyl monophosphoramidate intracellular prodrug of PMPA, in blood.

Authors:  E J Eisenberg; G X He; W A Lee
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2001 Apr-Jul       Impact factor: 1.381

5.  Activation mechanisms of nucleoside phosphoramidate prodrugs.

Authors:  C L Freel Meyers; R F Borch
Journal:  J Med Chem       Date:  2000-11-02       Impact factor: 7.446

6.  Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue.

Authors:  William A Lee; Gong-Xin He; Eugene Eisenberg; Tomas Cihlar; Swami Swaminathan; Andrew Mulato; Kenneth C Cundy
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

7.  Vγ9Vδ2 TCR-activation by phosphorylated antigens requires butyrophilin 3 A1 (BTN3A1) and additional genes on human chromosome 6.

Authors:  Felipe Riaño; Mohindar M Karunakaran; Lisa Starick; Jianqiang Li; Claus J Scholz; Volker Kunzmann; Daniel Olive; Sabine Amslinger; Thomas Herrmann
Journal:  Eur J Immunol       Date:  2014-06-30       Impact factor: 5.532

Review 8.  Immunosurveillance by human γδ T lymphocytes: the emerging role of butyrophilins.

Authors:  Dieter Kabelitz; Marcus Lettau; Ottmar Janssen
Journal:  F1000Res       Date:  2017-06-05

Review 9.  The ProTide Prodrug Technology: From the Concept to the Clinic.

Authors:  Youcef Mehellou; Hardeep S Rattan; Jan Balzarini
Journal:  J Med Chem       Date:  2017-08-24       Impact factor: 7.446

Review 10.  Regulation of Immunity by Butyrophilins.

Authors:  David A Rhodes; Walter Reith; John Trowsdale
Journal:  Annu Rev Immunol       Date:  2016-01-11       Impact factor: 28.527

View more
  15 in total

1.  A power law function describes the time- and dose-dependency of Vγ9Vδ2 T cell activation by phosphoantigens.

Authors:  Chia-Hung Christine Hsiao; Andrew J Wiemer
Journal:  Biochem Pharmacol       Date:  2018-11-02       Impact factor: 5.858

2.  Stability and Efficiency of Mixed Aryl Phosphonate Prodrugs.

Authors:  Benjamin J Foust; Jin Li; Chia-Hung Christine Hsiao; David F Wiemer; Andrew J Wiemer
Journal:  ChemMedChem       Date:  2019-07-24       Impact factor: 3.466

3.  The ProTide Prodrug Technology: Where Next?

Authors:  Ashwag S Alanazi; Edward James; Youcef Mehellou
Journal:  ACS Med Chem Lett       Date:  2018-12-20       Impact factor: 4.345

4.  ω-Hydroxy isoprenoid bisphosphonates as linkable GGDPS inhibitors.

Authors:  Nazmul H Bhuiyan; Michelle L Varney; Deep S Bhattacharya; William M Payne; Aaron M Mohs; Sarah A Holstein; David F Wiemer
Journal:  Bioorg Med Chem Lett       Date:  2019-08-20       Impact factor: 2.823

5.  A Phosphoramidate Strategy Enables Membrane Permeability of a Non-nucleotide Inhibitor of the Prolyl Isomerase Pin1.

Authors:  Daniel M C Schwarz; Sarah K Williams; Maxwell Dillenburg; Carston R Wagner; Jason E Gestwicki
Journal:  ACS Med Chem Lett       Date:  2020-08-10       Impact factor: 4.345

Review 6.  Structure-Activity Relationships of Butyrophilin 3 Ligands.

Authors:  Andrew J Wiemer
Journal:  ChemMedChem       Date:  2020-05-26       Impact factor: 3.466

7.  Synthesis and Metabolism of BTN3A1 Ligands: Studies on Diene Modifications to the Phosphoantigen Scaffold.

Authors:  Nyema M Harmon; Michael M Poe; Xueting Huang; Rohit Singh; Benjamin J Foust; Chia-Hung Christine Hsiao; David F Wiemer; Andrew J Wiemer
Journal:  ACS Med Chem Lett       Date:  2022-01-27       Impact factor: 4.345

8.  A luciferase lysis assay reveals in vivo malignant cell sensitization by phosphoantigen prodrugs.

Authors:  Jin Li; Nicholas A Lentini; David F Wiemer; Andrew J Wiemer
Journal:  Biochem Pharmacol       Date:  2019-10-16       Impact factor: 5.858

9.  Synthesis and Metabolism of BTN3A1 Ligands: Studies on Modifications of the Allylic Alcohol.

Authors:  Nicholas A Lentini; Chloe M Schroeder; Nyema M Harmon; Xueting Huang; Megan A Schladetsch; Benjamin J Foust; Michael M Poe; Chia-Hung Christine Hsiao; Andrew J Wiemer; David F Wiemer
Journal:  ACS Med Chem Lett       Date:  2020-12-04       Impact factor: 4.345

10.  Incorporation of a FRET pair within a phosphonate diester.

Authors:  Nyema M Harmon; Xueting Huang; Chia-Hung Christine Hsiao; Andrew J Wiemer; David F Wiemer
Journal:  Bioorg Chem       Date:  2021-05-30       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.